Bruni B, Barolo P, Gadaleta G, Gamba Ansaldi S, Grassi G, Zerbinati A, Molinatti M, Salvetti E
Ann Osp Maria Vittoria Torino. 1984 Jul-Dec;27(7-12):185-213.
The literature of the past ten years shows that the introduction of highly purified heterologous and, lastly, homologous insulins has notably lowered the production of IgG and IgE specific insulin antibodies, but has not succeeded in completely eliminating clinical manifestations of the immune or hyper-immune response to insulin therapy. In particular, insulin allergy with or without lipodystrophy is still seen. Among the factors of insulin immunogenicity, there is a possible genetic control of the immune response in type I diabetes: determining HLA halloantigens (A, B, C, D) might identify specific immune response genes (Ir genes). Initial researches, performed until now almost exclusively upon diabetics treated with conventional heterologous insulin, seem to indicate a positive relationship between haplotype HLA - B15 - DR4 and an elevated immune response, whereas haplotypes HLA - B8 - DR3 and HLA - B18 - DR3 might protect against the formation of anti-insulin antibodies. Antigens D/DR3 and D/DR4 are known to be primitively associated to susceptibility for type I diabetes, whereas antigens B8, B15, B18 are secondarily associated to the rise in frequency of DR3 and DR4 for the "linkage disequilibrium" existing between alleles of B and D loci. The results of HLA typing are presented in 2 groups of insulin-dependent diabetics (ID) followed from an immunological viewpoint during therapy with monocomponent heterologous insulin for over 5 years. The first group is composed of 50 patients with low IgG anti-insulin antibody titers (less than 1 mU/ml, Christiansen: low responders); the second group is made up of 23 patients with high IgG anti-insulin antibody titers (greater than 2.5 mU/ml, Christiansen: high responders) and includes 5 subjects with insulin allergy (associated or not with insulin lipoatrophy) and high levels of insulin specific IgE antibodies. A study of the frequencies of various HLA-B antigens in both groups of patients, in regard to a control group of piemontese population, in relation to the intensity of association (relative risk) and to the statistical importance of frequencies, shows only a possible protective effect of the HLA-B18 phenotype (linkage disequilibrium with HLA - DR3) towards the production of anti-insulin antibodies and hyperimmune clinical manifestations, such as allergy. Reliable conclusions are not possible between low and high responders for the other phenotypes (HLA - B7, B8, B15) commonly implicated. HLA-B12 was noted in 3 of 5 patients with allergy, in 2 cases associated with B8.(ABSTRACT TRUNCATED AT 400 WORDS)
过去十年的文献表明,高纯度异源胰岛素以及最后同源胰岛素的引入显著降低了IgG和IgE特异性胰岛素抗体的产生,但未能完全消除胰岛素治疗免疫或超敏反应的临床表现。特别是,仍可见伴有或不伴有脂肪营养不良的胰岛素过敏。在胰岛素免疫原性因素中,I型糖尿病的免疫反应可能存在遗传控制:确定HLA组织相容性抗原(A、B、C、D)可能会识别特定的免疫反应基因(Ir基因)。迄今为止,几乎所有针对接受常规异源胰岛素治疗的糖尿病患者进行的初步研究似乎都表明,单倍型HLA - B15 - DR4与免疫反应增强之间存在正相关,而单倍型HLA - B8 - DR3和HLA - B18 - DR3可能会预防抗胰岛素抗体的形成。已知抗原D/DR3和D/DR4最初与I型糖尿病易感性相关,而抗原B8、B15、B18则因B和D位点等位基因之间存在的“连锁不平衡”而与DR3和DR4频率升高继发性相关。对两组胰岛素依赖型糖尿病患者(ID)进行了HLA分型结果展示,从免疫学角度对其进行了超过5年的单组分异源胰岛素治疗随访。第一组由50名IgG抗胰岛素抗体滴度较低(低于1 mU/ml,克里斯蒂安森:低反应者)的患者组成;第二组由23名IgG抗胰岛素抗体滴度较高(大于2.5 mU/ml,克里斯蒂安森:高反应者)的患者组成,其中包括5名患有胰岛素过敏(伴有或不伴有胰岛素脂肪萎缩)且胰岛素特异性IgE抗体水平较高的患者。对两组患者中各种HLA - B抗原的频率进行研究,并与皮埃蒙特人群的对照组进行比较,考虑关联强度(相对风险)和频率的统计学意义,结果显示仅HLA - B18表型(与HLA - DR3连锁不平衡)对抗胰岛素抗体产生和超敏临床表现(如过敏)可能具有保护作用。对于其他常见涉及的表型(HLA - B7、B8、B15),低反应者和高反应者之间无法得出可靠结论。在5名过敏患者中有3名检测到HLA - B12,其中2例与B8相关。(摘要截断于400字)